Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

ABSTRACT: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

DISEASE(S): Endometrial Cancer,Additional Indications Below For Module 4 And 5,Cervical Cancer,Small Cell Lung Cancer,Small Cell Lung Carcinoma,Advanced Solid Tumors,Colorectal Cancer,Bladder Cancer,Advanced Cancer,Endometrial Neoplasms,Pancreatic Cancer,Breast Cancer,Lung Neoplasms,Ovarian Cancer,Biliary Cancer,Prostatic Neoplasms,Gastric Cancer,Non-small Cell Lung Cancer,Prostate Cancer,Ovarian Neoplasms,Pancreatic Neoplasms

PROVIDER: 2358872 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR